Cancer News and Research

Latest Cancer News and Research

Spray dryer strengthens PharmaForm's portfolio of bioavailability enhancement solutions

PharmaForm, a contract pharmaceutical development and manufacturing organization and a wholly owned subsidiary of Akela Pharma Inc. (TSX: AKL), today announced that it has added aqueous and solvent spray drying to its portfolio of bioavailability enhancement solutions.

4 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

GSK's malaria vaccine trial containing Antigenics’ Stimulon adjuvant enrolls more than 5,000 children

Antigenics, Inc. today indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the world’s most clinically advanced malaria vaccine, is ongoing in seven African countries.

4 Nov 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.

4 Nov 2009

Shionogi files New Drug Application in Japan

BioCryst Pharmaceuticals, Inc. today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this filing, BioCryst will receive a regulatory milestone payment of $7 million under its agreement with Shionogi.

4 Nov 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008.

4 Nov 2009

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2009.

4 Nov 2009

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Exelixis, Inc. announced today that thirteen abstracts related to the company’s development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of XL147 and XL765 will be reported in four poster presentations.

4 Nov 2009

Majority of women smokers unaware of immediate and long term health risks

Many women are aware that smoking can lead to lung cancer, heart disease and premature death. But a recent survey conducted by Angus Reid on behalf of nicotine replacement therapy brands, NICODERM(R) and NICORETTE(R) reveals that the majority of Canadian women who smoke are not necessarily aware of the host of other impacts that smoking can have on their immediate and longer term health.

4 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

Scientific and medical community mourns the loss of Emeritus Professor James Boyer Brown

The scientific and medical community mourns the loss of our esteemed colleague and good friend Emeritus Professor James Boyer Brown AM, MSc (NZ), PhD (Edin), MSc (Melb), DSc (Edin), FRANZCOG (Ad Eundem), Life Member Fertility Society of Australia, Life Member Endocrine Society of Australia, who passed away on Saturday 31st October 2009, aged 90.

4 Nov 2009

Entest BioMedical files second patent application in the treatment of COPD

Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.

4 Nov 2009

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

NovaRx Corporation announced today that the Company has successfully negotiated and received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix® Phase III clinical trial in patients with Non-Small Cell Lung Cancer (NSCLC).

4 Nov 2009

BD reports revenues of $1.898 billion for the fourth quarter of 2009

BD (Becton, Dickinson and Company) today reported quarterly revenues of $1.898 billion for the fourth fiscal quarter ended September 30, 2009, representing an increase of 5 percent from the prior-year period, or 8 percent excluding the unfavorable impact from foreign currency translation.

From BD (Becton, Dickinson and Company) 4 Nov 2009

Comparative study reveals similar brain networks in human and monkey brains

A study published this week in PNAS provides a comprehensive comparative functional anatomy study in human and monkey brains which reveals highly similar brain networks preserved across evolution.

4 Nov 2009

Mold detection device from Universal Detection Technology

Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced today that it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold.

4 Nov 2009

Study on asbestos-related diseases in Libby launched

Over nearly a century, thousands of residents and workers in Libby, MT, have been exposed to asbestos-contaminated vermiculite ore, leading to markedly higher rates of lung disease and autoimmune disorders, and causing to Libby in 2002 to be added to the federal Environmental Protection Agency's "National Priorities List."

4 Nov 2009

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

Marking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior Minister of State for Trade and Industry and Education, S. Iswaran, at the Biopolis on Nov. 3, 2009.

4 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

New FDA-approved heart pump for high-risk patients

Cardiologists at the University of Illinois Medical Center are using a new heart pump that can be inserted without the need for surgery and allows them to treat high-risk patients with a procedure to unblock their heart arteries.

4 Nov 2009

Cancer News and Research

Latest Cancer News and Research

Spray dryer strengthens PharmaForm's portfolio of bioavailability enhancement solutions

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

GSK's malaria vaccine trial containing Antigenics’ Stimulon adjuvant enrolls more than 5,000 children

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Shionogi files New Drug Application in Japan

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Majority of women smokers unaware of immediate and long term health risks

Safeguard Scientifics reports financial results for the third quarter of 2009

Scientific and medical community mourns the loss of Emeritus Professor James Boyer Brown

Entest BioMedical files second patent application in the treatment of COPD

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

BD reports revenues of $1.898 billion for the fourth quarter of 2009

Comparative study reveals similar brain networks in human and monkey brains

Mold detection device from Universal Detection Technology

Study on asbestos-related diseases in Libby launched

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

Researchers to find better ways to manage chronic pain by treating neuroinflammation

New FDA-approved heart pump for high-risk patients

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in